It would be fantastic if they could just run trials there, but that takes money and product, etc. I have to believe BIOMM is a great partner in these trials for Covid, and would likely continue to be a great partner if results go as "expected" and they see the benefits of partnering with CYDY for additional studies in Brazil. This situation is just part of why I am so excited about CYDY at this point...I am aware of the general story behind the MOA of Leronlimab and binding to the CCR5 receptor, and the growing number of known and potential indications for CCR5-related diseases. But then to realize how the learning curve of CYDY's leaders has progressed (I understand, too bad they had to go thru a learning curve...but so be it and get over it) and the new staff has so much more expertise and how many studies and catalysts are getting closer and closer and including with good partners in other areas of the world where great medical needs are present...The party is closer than ever and it WILL GET STARTED!

TTM Alice